Toledo
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
77- Orthopaedic Surgery
- 77
Building a short list of biologics vendors
Orthopedic groups and surgery centers that bring in a new tissue or biologics line typically start by narrowing a list of distributors to those willing to put processing descriptions, donor-eligibility screening summaries, and lot-level documentation in writing before any product ships. A compliance lead or managing physician usually owns that review, since the decision touches both procurement and the practice's own regulatory risk. Comparing how a distributor documents sterility testing and quarantine release is often a faster way to narrow the list than comparing price alone, since pricing for these products is not publicly posted by any supplier.
- Certificate of analysis for the specific lot
- Donor eligibility screening summary
- Lot release and third-party sterility testing record
NPI verification and account setup
Precision Biologics opens accounts only for licensed healthcare professionals and verifies each applicant against the NPPES registry using the practice's NPI number before releasing pricing or accepting an order. This step is the same for a single-surgeon office and a multi-location surgery center; there is no separate onboarding track based on practice size. Pricing itself is never published and is shared only once an account has been verified.
Receiving cryopreserved shipments
Cryopreserved Wharton's jelly and exosome products are slow-rate frozen, stored at -80 degrees Celsius, and shipped overnight on dry ice in validated containers. A practice adding this category should plan a receiving process: a staff member available to accept a dry-ice shipment, confirm the lot identifier against the packing slip, and log that lot at the patient-record level once product is in use, since traceability is tracked by lot on the clinic side.
Confirming regulatory posture before ordering
Whether a specific intended use in an orthopedic setting falls under 21 CFR 1271.10's framework for minimally manipulated, homologous-use tissue is a determination the practice and its own counsel need to make; Precision Biologics does not advise on clinical use, dosing, or procedure. Practices in Ohio should also confirm their medical director's standing with the Ohio State Medical Board as part of normal vendor due diligence. Once that review is complete, Precision Biologics supports account setup with physician-level documentation conversations and the records needed to complete a verified account.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Does Precision Biologics have staff or a warehouse located in Toledo?+
No. Accounts are opened and managed remotely, and product ships nationally from the distributor's cold-chain network rather than from a local office.
What should a Toledo surgery center ask for before adding a new tissue product line?+
Request the certificate of analysis, donor eligibility summary, and lot release record for the specific lot being considered; these are available to verified accounts on request.
Who determines whether a particular orthopedic use qualifies under the HCT/P framework?+
That determination belongs to the practice and its own regulatory counsel under 21 CFR 1271.10. Precision Biologics supplies documentation but does not advise on clinical use.